Argyle Capital Partners’s Pfizer PFE Stock Holding History

Argyle Capital Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$313K	Sell	10,987 -2,424	-18%	-$64.5K	0.19%	124
2026 Q2	$323K	Sell	13,411 -1,099	-8%	-$28.7K	0.2%	126
2026 Q1	$407K	Buy	14,510 +606	+4%	+$16.1K	0.29%	96
2025 Q4	$346K	Buy	13,904 +1,261	+10%	+$31.8K	0.25%	105
2025 Q3	$322K	Sell	12,643 -1,330	-10%	-$32.8K	0.23%	121
2025 Q2	$339K	Buy	13,973 +1,686	+14%	+$39.3K	0.28%	102
2025 Q1	$311K	Sell	12,287 -1,795	-13%	-$47K	0.27%	99
2024 Q4	$374K	Buy	+14,082	New	+$382K	0.32%	89

Other funds holding PFE

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Argyle Capital Partners's PFE Position: Q3 2026 in Review

Argyle Capital Partners reduced its Pfizer (PFE) stake by 18% in Q3 2026, selling an estimated $64.5K and leaving 10,987 shares worth $313K. The position accounts for 0.19% of the portfolio, ranked #124.

Argyle Capital Partners first reported a position in PFE in Q4 2024 and has held it in 8 quarters since. The position peaked at $407K in Q1 2026. 1,767 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

Argyle Capital Partners held 10,987 shares of Pfizer worth $313K as of Q3 2026.
Argyle Capital Partners sold 2,424 Pfizer shares in Q3 2026, an estimated $64.5K.
Pfizer made up 0.19% of Argyle Capital Partners's portfolio in Q3 2026, its #124 holding.
Argyle Capital Partners first reported a position in Pfizer in Q4 2024 and has held it in 8 quarters since.
Argyle Capital Partners's Pfizer position peaked at $407K in Q1 2026.
1,767 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Argyle Capital Partners's 13F filing for Q3 2026, filed 23 Oct 2026.